![]() |
|
|
,**,2




* North Shore-Long Island Jewish Research Institute, Manhasset, NY 11030;
Department of Otolaryngology, Long Island Jewish Medical Center, The Long Island Campus of Albert Einstein College of Medicine, New Hyde Park, NY 11040;
** Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY 10461;
Laboratories and Pediatrics, North Shore University Hospital and

Department of Medicine, North Shore University Hospital, Manhasset, NY 11030; and

Renal Electrolyte and Hypertension Division, University of Pennsylvania Medical Center, Philadelphia, PA 19104
2To whom correspondence should be addressed. E-mail: kauborn{at}nshs.edu.
| ABSTRACT |
|---|
|
|
|---|
-hydroxyestrone was increased in I3C-fed mice. These findings demonstrate a profound effect of dietary I3C in experimental SLE.
KEY WORDS: autoimmunity systemic lupus erythematosus indole-3-carbinol anti-DNA antibodies glomerulonephritis
Autoimmune disorders, which include systemic lupus erythematosus (SLE),2 affect as much as 20% of the population inWestern countries (1). Treatment requires high doses of immunosuppressive agents, given over prolonged periods of time. SLE and the side effects of therapeutic drugs place heavy burdens on patients (2). Nutritional modulation offers the prospect of delaying or suppressing the effects of SLE, potentially decreasing the need for or amount of medication. Dietary fish oil rich in (n-3) PUFA (3) or food restriction (4) ameliorate autoimmune diseases in mice. Human studies support the efficacy of fish oil (5). A food-restricted diet combined with fish oil extends lifespan even more in mice (6). Some data suggest that diets high in animal fat exacerbate SLE (7), whereas vegetarian diets may ameliorate some symptoms (8).
A disproportionate number of women develop SLE (9). Abnormal estrogen metabolism, which prolongs estrogenic effects, is found in women with SLE (10). In the (NZB/NZW) F1 mice used in the present study, females die of lupus at 812 mo of age, whereas males die at 1520 mo (11). Administration of estradiol to mice expressing a transgene for the heavy chain of an anti-DNA antibody induces a lupus-like phenotype (12). Because indole-3-carbinol (I3C), which is abundant in cruciferous vegetables, is an antiestrogen, we hypothesized that it might prevent, delay or even represent an adjunct treatment for SLE. I3C shifts estrogen metabolism toward less estrogenic metabolites (13) and is a negative regulator of signaling that is dependent on the estrogen receptor (14). Many genes activated by estrogen are abrogated by diindolylmethane, a condensation product of I3C (15). We evaluated the effect of a supplement of I3C, at a level obtainable from diet (16), on the outcome of SLE in lupus-prone (NZB x NZW) F1 mice.
| MATERIALS AND METHODS |
|---|
|
|
|---|
Female NZB/NZW F1 mice were obtained from the Jackson Laboratory (Bar Harbor, ME). AIN76A diets (17) ± 0.2 g/kg I3C (Sigma, St. Louis, MO) were prepared by Ziegler (Gardner, PA). The AIN76A diet supplies a total of 18.5 MJ/kg with 22% of energy from protein, 11% from fat and 67% from carbohydrates. The nonpurified diet was Harlan Teklad Rodent Chow (Madison, WI). Two feeding protocols were evaluated in parallel with identical sample collections. Early start mice (n = 20) were fed AIN76A diet ± I3C from 1.2 mo of age to determine whether I3C would prevent SLE. Late start mice (n = 20) were fed the nonpurified diet for 5 mo and then fed the AIN76A diet ± I3C, to determine whether I3C ameliorated SLE. Mice consumed their diets ad libitum. Consumption was monitored to ensure comparable intake. Serum, obtained monthly by orbital bleeding, was evaluated for anti-double-stranded DNA (dsDNA) antibodies. Urine samples were collected and evaluated for proteinuria each month early in life and more frequently later. Urine collected at 7 mo was used to measure estrogen metabolites. A subset of mice was killed at 12.5 mo of age, and kidneys removed for evaluation. Lifespan was determined by excessive proteinuria (
5g/L); mice were killed by CO2 overdose or unanticipated death. A follow-up study was done with mice (n = 18) fed the AIN76A diets ± I3C from 5 mo and killed at 1213 mo for kidney evaluation. The study was approved by the Institutional Animal Care and Use Committee at North Shore University Hospital.
Anti-dsDNA antibodies.
The ELISA assay for dsDNA antibody was performed as described previously (18). Aliquots (100 µL) of 1:100 diluted serum were incubated overnight at 4°C on high binding microtiter plates (Corning, Acton, MA) coated with calf thymus dsDNA (10 mg/L; Worthington, Lakewood, NJ), and blocked with 10% fetal bovine serum. After being washed with PBS-Tween20 (0.1%, pH 7.2), 100 µL of 1:1000 diluted peroxidase-conjugated goat anti-mouse IgG (Sigma) was added and incubated for 1 h followed by the addition of 100 µL of a working dilution of peroxidase substrate-phenol and 4-aminoantipyrine (Eastman Kodak, Rochester, NY) in phosphate buffer (pH 7.2 and 0.1 mol/L). After development of color, the optical density (OD) at 490 nm was determined.
Estrogen metabolites.
Urine was collected in chambers of metabolic cages with 100 mg of ascorbic acid. 2-Hydroxyestrone (2-OHE) and 16
-hydroxyestrone (16
-OHE) were measured as described previously (19) using the Estramet ELISA kit (Immunacare, Lehigh, PA). The assay is a competitive enzyme immunoassay in which binding of the antigen-enzyme conjugate to immobilized antibody is inhibited by the addition of free antigen.
Renal pathology.
Protein in urine was evaluated using Chemstrips (Boehringer Mannheim, Indianapolis, IN). Glomerular disease was evaluated by multiple methods. Using formalin-fixed 5-µm kidney sections stained with hematoxylin and eosin, glomerular nephritis (glomerular enlargement, hypercellularity/proliferation, crescents, sclerosis) and intrastitial nephritis (infiltrates, necrosis, fibrosis) were measured semiquantitatively (04+) using a standard score for severity (20). Immunofluorescence was detected in 8-µm sections, which had been frozen in optimal cutting temperature solution (Sakura Finetek, Torrance, CA), using fluorescein-5-isothiocyanatelabeled anti-mouse IgG. For electron microscopy (EM), the renal cortex was fixed in 200 mmol/L glutaraldehyde, postfixed in 39 mmol/L osmium tetroxide in 100mmol/L sodium cacodylate (pH 7.3), stained in bloc with 118 mmol/L uranyl acetate in 50 mmol/L sodium acetate, 26 mmol/L sodium barbital buffer (pH 6.8), dehydrated in graded ethanols and embedded in Effaposy resin (EM Sciences, Ft. Washington, PA). Sections (50100 nm) were examined on a JEM 100CXII transmission EM (JEOL, Tokyo, Japan). The severity of epithelial foot effacement was evaluated semiquantitatively (04+) and the presence and site of electron-dense deposits due to immune complex deposition were determined.
Statistics.
Survival for each cohort was analyzed monthly using the product-limit method and compared using the log-rank test (SAS Institute, Cary, NC). Other analyses included independent t test (anti-dsDNA antibodies, estrogen metabolites) and
2 testing (proteinuria and kidney morphology scores). Data were analyzed using Microsoft Excel software.
| RESULTS |
|---|
|
|
|---|
Dietary I3C extended the life span of NZB x NZW F1 mice (Fig. 1). Control mice began to die at 8 mo. For the early start mice, survival was longer for those fed I3C (P < 0.0008). At 12 mo, 10% of controls and 80% of I3C-fed mice were alive. Survival for late start I3C-fed mice was also longer (P < 0.0011). At 12 mo, 30% of controls and 100% of I3C-fed mice were alive. Survival of mice in the early start and late start protocols did not differ. A set of I3C-fed mice lived to 20.5 mo of age.
|
I3C treatment did not affect the development of anti-dsDNA antibodies (Fig. 2), which were detectable at 5 mo and continued to rise over time. Lower titers were present in I3C-treated mice at 7 mo of age (P < 0.05) in both early and late start feeding protocols with the greatest difference at 8 mo. This trend did not continue, and levels of antibodies became indistinguishable. This discrepancy may have been due to increased deaths in controls; analyses of later times included only surviving mice.
|
I3C delayed pathological deterioration of kidneys. Proteinuria was lower in I3C-treated mice, regardless of the time treatment was initiated. An estimated 300 mg/L of protein was detected in urine in almost all mice as early as 7 mo of age (not shown). However, the number of mice with 5 g/L of proteinuria rose more quickly in the controls than either I3C-fed group (Fig. 3). Morphologically, there was less severe renal damage between 12 and 13 mo of age in mice fed I3C (Fig. 4). Glomeruli of the I3C groups were generally similar to those of normal nonlupus-prone BALB/c mice. In the untreated (NZB x NZW) F1 mice, histological changes included thickening of glomerular capillary loops, nodular expansion of the mesangium and tubular casts. IgG staining was barely evident in normal BALB/c mouse kidneys, weak in I3C-treated mice, but glomerular staining for IgG was intense in untreated (NZB x NZW) F1 controls. Semiquantitative results (Table 1) indicated that the difference in severity of kidney disease (glomerulonephritis and interstitial nephritis) was significantly less in I3C-fed mice. In EM studies (Fig. 5, Tables 1, and 2), untreated controls had more extensive glomerular lesions with increased immune complex deposition (granular electron dense deposits) compared with I3C groups. Large subepithelial deposits with spikes and diffuse effacement of visceral epithelial cell foot processes were readily evident in untreated groups but only occasionally seen in the I3C-fed mice.
|
|
|
|
|
The ratio of 2-OHE to 16
-OHE in urine at 7 mo of age, was greater than in controls in I3C-treated mice given I3C early (P < 0.002) and later (P < 0.04) in life (Fig. 6), consistent with less estrogenic activity in mice fed I3C.
|
| DISCUSSION |
|---|
|
|
|---|
Our findings suggest that I3C suppresses an autoimmune inflammatory response, delaying renal failure due to glomerulonephritis. It is difficult to evaluate precisely the effects of I3C on the development of anti-dsDNA antibodies. The mode by which I3C affects the immune system in SLE may be complex and involve actions other than direct antibody suppression. Tamoxifen, like I3C, often behaves as an antiestrogen, decreasing cytokines and suppressing renal damage in autoimmune (NZB x NZW) F1 and MRL-lpr/lpr mice (21,22).
Estrogen metabolism was clearly altered in our I3C-treated mice. The ratio of 2-OHE to16
-OHE was increased by I3C, a result consistent with less estrogenic activity. 16
-OHE binds covalently to the estrogen receptor (23) and has a prolonged estrogenic effect (24), whereas 2-OHE is not estrogenic (25). Lupus patients have decreased 2-hydroxylation (10) and thus increased estrogenic activities. I3C increases 2-hydroxylation (13), and the relative use of the alternate pathways of hydroxylation of estrone is reflected by excretion of the metabolites. Other activities of I3C result in growth arrest and apoptosis (26,27), activities that could occur in lymphoid cells. A similar change in estrogen metabolism occurred in a study of 17 women with SLE given I3C (28). However, no effects were observed on SLE symptoms in a 3-mo observation period. Longer studies are required to clarify some of these issues.
This study adds I3C to the list of nutrients that may have beneficial effects on the outcome of SLE. Dietary I3C has few side effects and has been in clinical use for treatment of laryngeal papillomatosis (29) and precancerous lesions of the cervix (30). Mechanisms by which I3C extends the life span of mice remain to be determined. Although the antiestrogenic activities of this compound are likely to be important, I3C may have direct effects on other immunologic or inflammatory processes.
| ACKNOWLEDGMENTS |
|---|
| FOOTNOTES |
|---|
3 Abbreviations used: dsDNA, double-stranded DNA; EM, electron microscopy; I3C, indole-3-carbinol; 2-OHE, 2-hydroxyestrone; 16
-OHE, 16
-hydroxyestrone; SLE, systemic lupus erythematosus. ![]()
Manuscript received 21 February 2003. Initial review completed 30 March 2003. Revision accepted 23 July 2003.
| LITERATURE CITED |
|---|
|
|
|---|
1. Cervera, R. (2001) The epidemiology and significance of autoimmune diseases in health care. Scand. J. Clin. Lab. Investig. Suppl. 235:27-30.[Medline]
2. Davidson, A. & Diamond, B. (2001) Autoimmune diseases. N. Engl. J. Med. 345:340-350.
3. Wu, W. M., Chiang, B. L., Chang, S. C. & Lin, B. F. (2000) Late feeding of dietary fish oil alleviates disease severity and affects macrophage function in autoimmune NZB/W F1 mice. J. Microbiol. Immunol. Infect. 33:79-86.[Medline]
4. Fernandes, G., Friend, P., Yunis, E. J. & Good, R. A. (1978) Influence of dietary restriction on immunologic function and renal disease in (NZB x NZW) F1 mice. Proc. Natl. Acad. Sci. U.S.A. 75:1500-1504.
5. Kehn, P. & Fernades, G. (2001) The importance of omega-3-fatty acids in the attenuation of immune-mediated diseases. J. Clin. Immunol. 21:99-101.[Medline]
6. Jolly, C. A., Muthukumar, A., Avula, C. P., Troyer, D. & Fernades, G. (2001) Life span is prolonged in food-restricted autoimmune-prone (NZB x NZW)F(1) mice fed a diet enriched with (n-3) fatty acids. J. Nutr. 131:2753-2760.
7. Leiba, A., Amital, H., Gershwin, M. E. & Shoenfeld, Y. (2001) Diet and lupus. Lupus 10:246-248.
8. McCarty, M. F. (2001) Upregulation of lymphocyte apoptosis as a strategy for preventing and treating autoimmune disorders: a role for whole-food vegan diets, fish oil and dopamine agonists. Med. Hypotheses 57:258-275.[Medline]
9. Whitacre, C. C., Reingold, S. C. & OLooney, P. A. (1999) A gender gap in autoimmunity. Science (Washington, D.C.) 283:1277-1278.
10. Lahita, R. G., Bradlow, H. L., Kunkel, H. G. & Fishman, J. (1979) Alterations of estrogen metabolism in systemic lupus erythematosus. Arthritis Rheum. 22:1195-1198.[Medline]
11. Theofilopoulos, A. N. & Dixon, F. J. (1985) Murine models of systemic lupus erythematosus. Adv. Immunol. 37:269-390.[Medline]
12. Bynoe, M. S., Grimaldi, C. M. & Diamond, B. (2000) Estrogen up-regulates Bcl-2 and blocks tolerance induction of naive B cells. Proc. Natl. Acad. Sci. U.S.A. 97:2703-2708.
13. Michnovicz, J. J., Adlercreutz, H. & Bradlow, H. L. (1997) Changes in levels of urinary estrogen metabolites after oral indole-3-carbinol treatment in humans. J. Natl. Cancer Inst. 89:718-723.
14. Meng, Q., Yuan, F., Goldberg, I. D., Rosen, E. M., Auborn, K. & Fan, S. (2000) Indole-3-carbinol is a negative regulator of estrogen receptor-
signaling in human tumor cells. J. Nutr. 130:2927-2931.
15. Chen, I., Hsieh, T., Thomas, T. & Safe, S. (2001) Identification of estrogen-induced genes downregulated by AhR agonists in MCF-7 breast cancer cells using suppression subtractive hybridization. Gene 262:207-214.[Medline]
16. Scones, K., Heaney, R. K. & Fenwick, G. R. (1984) An estimate of the mean daily intake of glucosinolates from cruciferous vegetables in the UK. J. Sci. Food Agric. 35:712-720.
17. American Institute of Nutrition (1977) Report of the American Institute of Nutrition ad hoc committee for nutritional studies. J. Nutr. 107:1340-1345.
18. Kaplan, S., Hyman, K., Brooks, R., Wakai, M., Hashimoto, S., Furie, R. & Chiorazzi, N. (1993) Monoclonal IgM, IgG, and IgA human rheumatoid factors produced by synovial tissue-derived, EBV-transformed B cell lines. Clin. Immunol. Immunopathol. 1:18-25.
19. Auborn, K., Abramson, A., Bradlow, H. L., Sepkovic, D. & Mullooly, V. (1998) Estrogen metabolism and laryngeal papillomatosis: a pilot study on dietary prevention. Anticancer Res. 18:4569-4574.[Medline]
20. Chan, O., Madaio, M. P. & Shlomchik, M. J. (1997) The roles of B cells in MRL/lpr murine lupus. Ann. N.Y. Acad. Sci. 815:75-87.
21. Wu, W. M., Lin, B. F., Su, Y. C., Suen, J. L. & Chiang, B. L. (2000) Tamoxifen decreases renal inflammation and alleviates disease severity in autoimmune NZB/W F1 mice. Scand. J. Immunol. 52:393-400.[Medline]
22. Wu, W. M., Suen, J. L., Lin, B. F. & Chiang, B. L. (2000) Tamoxifen alleviates disease severity and decreases double negative T cells in autoimmune MRL-lpr/lpr mice. Immunology 100:110-1l8.[Medline]
23. Swaneck, G. E. & Fishman, J. (1988) Covalent binding of the endogenous estrogen 16 alpha-hydroxyestrone to estradiol receptor in human breast cancer cells: characterization and intranuclear localization. Proc. Natl. Acad. Sci. U.S.A. 85:7831-7835.
24. Lustig, R. H., Mobbs, C. V., Pfaff, D. W. & Fishman, J. () Temporal actions of 16 alpha-hydroxyestrone in the rat: comparisons of lordosis dynamics with other estrogen metabolites and between sexes. J. Steroid Biochem. 33:417-421.
25. Schneider, J., Huh, M. M., Bradlow, H. L. & Fishman, J. (1984) Antiestrogen action of 2-hydroxyestrone on MCF-7 human breast cancer cells. J. Biol. Chem. 25:4840-4845.
26. Cover, C. M., Hsieh, S. J., Tran, S. H., Hallden, G., Kim, G. S., Bjeldanes, L. F. & Firestone, G. L. (1998) Indole-3-carbinol inhibits the expression of cyclin-dependent kinase-6 and induces a G1 cell cycle arrest of human breast cancer cells independent of estrogen receptor signaling. J. Biol. Chem. 273:3838-3847.
27. Chen, D-Z., Qi, M., Auborn, K. J. & Carter, T. H. (2002) Indole-3-carbinol and diindolylmethane induce apoptosis of human cervical cancer cells and in murine HPV16-transgenic preneoplastic cervical epithelium. J. Nutr. 131:3394-3302.
28. McAlindon, T. E., Gulin, J., Chen, T., Klug, T., Lahita, R. & Nuite, M. (2001) Indole-3-carbinol in women with SLE: effect on estrogen metabolism and disease activity. Lupus 10:779-783.
29. Rosen, C. A., Woodson, G. E., Thompson, J. W., Hengesteg, A. P. & Bradlow, H. L. (1998) Preliminary results of the use of indole-3-carbinol for recurrent respiratory papillomatosis. Otolaryngol. Head Neck Surg. 118:810-815.[Medline]
30. Bell, M. C., Crowley-Nowick, P., Bradlow, H. L., Sepkovic, D. W., Schmidt-Grimminger, D., Howell, P., Mayeaux, E. J., Tucker, A., Turbat-Hferrera, E. A. & Mathis, J. M. (2000) Placebo-controlled trial of indole-3-carbinol in the treatment of CIN. Gynecol. Oncol. 78:123-129.[Medline]
This article has been cited by other articles:
![]() |
Y. Hong, T. Wang, C. Huang, W. Cheng, and B. Lin Soy isoflavones supplementation alleviates disease severity in autoimmune-prone MRL-lpr/lpr mice Lupus, September 1, 2008; 17(9): 814 - 821. [Abstract] [PDF] |
||||
![]() |
J. Cohen-Solal, V Jeganathan, L Hill, D Kawabata, D Pinto-Rodriguez, C Grimaldi, and B Diamond Hormonal regulation of B-cell function and systemic lupus erythematosus Lupus, June 1, 2008; 17(6): 528 - 532. [Abstract] [PDF] |
||||
![]() |
Z. Yu, B. Mahadevan, C. V. Lohr, K. A. Fischer, M. A. Louderback, S. K. Krueger, C. B. Pereira, D. J. Albershardt, W. M. Baird, G. S. Bailey, et al. Indole-3-carbinol in the maternal diet provides chemoprotection for the fetus against transplacental carcinogenesis by the polycyclic aromatic hydrocarbon dibenzo[a,l]pyrene Carcinogenesis, October 1, 2006; 27(10): 2116 - 2123. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. J. Auborn Can Indole-3-Carbinol-Induced Changes in Cervical Intraepithelial Neoplasia Be Extrapolated to Other Food Components? J. Nutr., October 1, 2006; 136(10): 2676S - 2678S. [Full Text] [PDF] |
||||
![]() |
J. A. Savino III, J. F. Evans, D. Rabinowitz, K. J. Auborn, and T. H. Carter Multiple, disparate roles for calcium signaling in apoptosis of human prostate and cervical cancer cells exposed to diindolylmethane. Mol. Cancer Ther., March 1, 2006; 5(3): 556 - 563. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||